New Zealand markets closed

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.40+0.02 (+0.31%)
At close: 04:00PM EDT
6.40 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 117.48M
Enterprise value 98.01M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)8.38
Enterprise value/revenue N/A
Enterprise value/EBITDA -7.38

Trading information

Stock price history

Beta (5Y monthly) 0.44
52-week change 3-62.29%
S&P500 52-week change 326.27%
52-week high 318.65
52-week low 35.92
50-day moving average 38.06
200-day moving average 39.75

Share statistics

Avg vol (3-month) 3103.42k
Avg vol (10-day) 3126.54k
Shares outstanding 518.36M
Implied shares outstanding 618.6M
Float 86.63M
% held by insiders 155.38%
% held by institutions 116.44%
Shares short (30 Apr 2024) 4943.97k
Short ratio (30 Apr 2024) 414.3
Short % of float (30 Apr 2024) 410.26%
Short % of shares outstanding (30 Apr 2024) 45.14%
Shares short (prior month 28 Mar 2024) 4808.23k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-77.22%
Return on equity (ttm)-170.23%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-22.38M
Diluted EPS (ttm)-1.41
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)19.46M
Total cash per share (mrq)1.06
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.46
Book value per share (mrq)0.76

Cash flow statement

Operating cash flow (ttm)-15.54M
Levered free cash flow (ttm)-7.02M